trial · primary record
ORM-1153
CD123+ Acute Myeloid Leukemia
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2029-12 |
| Primary endpoint | Optimal Biological Dose(s) of ORM-1153 |
| Registry ID | NCT07809906 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:38.785Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07809906
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.